Main Sequence Ventures is a venture capital that is interested in building global industries. The firm was founded by Bill Bartee, Martin Duursma, Mike Nicholls, Mike Zimmerman, and Phil Morle, in 2017, in Sydney, New South Wales, Australia.
The firm is interested in companies that leverage deep tech and frontier technologies. Investments go to companies such as CSIRO, Advanced Navigation, v2food, Q-CTRL, Kapiche, and Lumachain. Main Sequence Ventures is interested in being a lead investor during Series A through B, seed, and venture rounds.
Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.